PMADS

Id:	acc2588
Group:	2sens
Protein:	CDKN1B
Gene Symbol:	CDKN1B
Protein Id:	P46527
Protein Name:	CDN1B_HUMAN
PTM:	phosphorylation
Site:	unclear
Site Sequence:
Disease Category:	Cancer
Disease:	Breast Cancer
Disease Subtype:	TNBC
Disease Cellline:
Disease Info:
Drug:	NP-ALT
Drug Info:	-
Effect:	modulate
Effect Info:	"NP-ALT inhibits the tyrosine phosphorylation of p27Kip1 (CDKN1B), and then inhibits CDK4/6 and CDK2, thereby affecting tumors."
Note:
Score:	4.0
Pubmed(PMID):	34446542
Sentence Index:	34446542_2-3
Sentence:	"Here we describe a novel strategy to prevent CDK4i resistance by using a therapeutic liposomal:peptide formulation, NP-ALT, to inhibit the tyrosine phosphorylation of p27Kip1(CDKN1B), which in turn inhibits both CDK4/6 and CDK2. We find that NP-ALT blocks proliferation in HR+ breast cancer cells, as well as CDK4i-resistant cell types, including triple negative breast cancer (TNBC)."

Sequence & Structure:

MSNVRVSNGSPSLERMDARQAEHPKPSACRNLFGPVDHEELTRDLEKHCRDMEEASQRKWNFDFQNHKPLEGKYEWQEVEKGSLPEFYYRPPRPPKGACKVPAQESQDVSGSRPAAPLIGAPANSEDTHLVDPKTDPSDSQTGLAEQCAGIRKRPATDDSSTQNKRANRTEENVSDGSPNAGSVEQTPKKPGLRRRQT

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CDKN1B-Ser10
Cancer	Intensity
BRCA	0.427
COAD	0.021
HGSC	1.815
ccRCC	-0.291
GBM	0.132
HNSC	0.113
LUAD	0.655
LUSC	0.426
non_ccRCC	-1.023
PDAC	-0.097
UCEC	-2.178

CDKN1B-Ser12
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CDKN1B-Ser140
Cancer	Intensity
BRCA	0.376
COAD	0.429
HGSC	-1.793
ccRCC	0.407
GBM
HNSC
LUAD	0.568
LUSC	0.999
non_ccRCC
PDAC
UCEC	-0.987

CDKN1B-Ser178
Cancer	Intensity
BRCA
COAD	0.468
HGSC	-2.354
ccRCC	0.746
GBM	0.415
HNSC
LUAD	0.472
LUSC	0.349
non_ccRCC
PDAC	0.234
UCEC	-0.33

CDKN1B-Ser7
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.436
GBM
HNSC	0.509
LUAD	0.553
LUSC
non_ccRCC
PDAC
UCEC	-1.498

CDKN1B-Thr142
Cancer	Intensity
BRCA
COAD	-0.707
HGSC
ccRCC	0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CDKN1B-Thr157
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

CDKN1B-Thr42
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.05
GBM
HNSC	-0.974
LUAD
LUSC
non_ccRCC
PDAC	1.024
UCEC

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
-	-	U	Corticotroph tumor	Phosphorylation	12050228
-	-	U	T-cell acute lymphoblastic leukemia	Ubiquitination	34407842
-	-	U	Hepatocellular carcinoma	Ubiquitination	33589597
-	-	U	Acute myeloid leukemia	Ubiquitination	29209041
-	-	U	Breast cancer	Ubiquitination	35813480
-	-	U	Glioblastoma	Ubiquitination	36792756

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb